SCHEMBL26017593

SCHEMBL26017593

Cc1ccc2nc(-c3noc(-c4ccnc(C)c4)n3)ccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 3/20 0.49
▸ S1PR3 Q99500 1/20 0.49
▸ GRM5 P41594 1/20 0.47
▸ NPC1 O15118 7/20 0.44
▸ RAB9A P51151 7/20 0.44
▸ MEN1 O00255 6/20 0.44
▸ KMT2A Q03164 6/20 0.44
▸ TP53 P04637 3/20 0.44
▸ PKM P14618 3/20 0.44
▸ KDM4E B2RXH2 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ TSHR P16473 3/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ GAA P10253 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ KLF5 Q13887 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21771094 0.87 S1PR1 (0.57) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL26017513 0.86 TP53 (0.50) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL13453336 0.78 NPC1 (0.67) S1PR1S1PR3NPC1RAB9AMEN1
SCHEMBL21273251 0.76 S1PR1 (0.53) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL21273246 0.75 S1PR1 (0.52) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL21771256 0.73 S1PR1 (0.55) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL21273259 0.72 S1PR1 (0.48) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL21273256 0.72 S1PR1 (0.48) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL21273263 0.71 MAPT (0.49) S1PR1S1PR3GRM5NPC1RAB9A
SCHEMBL14329053 0.70 S1PR1 (0.74) S1PR1S1PR3NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2023-07-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11707452-B2 Modulators of alpha-synuclein proteolysis and associated methods of use UCHL1, ADRM1, CRBN S1PR1 4067/4885S1PR3 4519/4885GRM5 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback